Related Experiment Video
Updated: Jan 4, 2026
10:01
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
7.8K
18F-PSMA 1007 Uptake in Brain Metastases From Breast Cancer
Fahad Marafi1, Arun Sasikumar2, Mahmoud Alfeeli1
1From the Jaber Alahmad Centre for Molecular Imaging, Shuwaikh, Kuwait.
Clinical Nuclear Medicine
|November 7, 2019
Summary
Fluorine-18 PSMA-1007 PET/CT imaging shows potential for detecting recurrent brain metastases in breast cancer patients. This novel approach may enable future theranostic applications for non-prostate cancer brain metastases.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiochemistry
Background:
- Metastatic breast cancer can lead to brain metastases, posing a significant clinical challenge.
- Accurate detection and characterization of brain metastases are crucial for effective treatment planning.
- Current imaging modalities may have limitations in detecting small or recurrent brain lesions.
Observation:
- A 64-year-old woman with metastatic breast cancer presented with suspected recurrent brain metastases.
- The patient underwent imaging with F-FDG PET/CT, F-PSMA 1007 PET/CT, and brain MRI.
- F-PSMA 1007 PET/CT demonstrated intense tracer uptake in a suspected lesion and identified two additional metastatic lesions.
Findings:
- F-PSMA 1007 PET/CT successfully localized a recurrent brain metastasis in the right parietal lobe.
- The imaging also detected two previously undetected metastatic brain lesions, confirmed by subsequent MRI.
- These findings suggest F-PSMA 1007 PET/CT is feasible for imaging brain metastases from non-prostate primary cancers.
Implications:
- F-PSMA 1007 PET/CT shows promise as a diagnostic tool for brain metastases in breast cancer.
- The tracer's localization characteristics suggest potential for theranostic applications, similar to PSMA-617.
- This imaging technique could expand the utility of PSMA-targeted agents beyond prostate cancer.
